Principia Biopharma

Sanofi's tolebrutinib woes pile up with FDA delay, trial miss

Sanofi's stockings may hang empty this holiday season—at least when it comes to tolebrutinib in non-relapsing secondary progressive multiple sclerosis.

Eric Sagonowsky Dec 15, 2025 9:30am

eraser pencil mistake write cut pen scrub out

Sanofi cuts programs tied to multibillion-dollar deals

Jan 30, 2025 9:05am

An arrow incrementally going up stairs before pointing straight up Blue background

Sanofi nails phase 3 LUNA landing, sparking race to regulators

Apr 23, 2024 2:23am

Sanofi reports setbacks to Denali, Kymab and Principia assets

Oct 27, 2023 6:25am

Still under partial hold, Sanofi makes case for safety of MS med

Apr 28, 2023 11:16am

Sanofi, after $8B outlay, sees M&A strategy deliver 2 more duds

Apr 27, 2023 7:41am